AxoGen (NASDAQ:AXGN) Sets New 12-Month High – Here’s What Happened

AxoGen, Inc. (NASDAQ:AXGN)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $43.47 and last traded at $44.5750, with a volume of 85739 shares changing hands. The stock had previously closed at $39.39.

Trending Headlines about AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Two brokerages raised their price targets and stayed bullish, implying upside from current levels — Citizens Jmp raised its target to $50 with a “market outperform” rating, and Wells Fargo lifted its target to $48 with an “overweight” rating. Price Target Raises
• Positive Sentiment: Axogen will present at the 2026 Bank of America Global Healthcare Conference, giving management a platform to discuss growth drivers, margin progress and commercialization milestones — a potential near‑term visibility event for investors. Axogen to Participate in BofA Conference
• Neutral Sentiment: Company released full Q1 2026 earnings materials and the earnings‑call transcript/presentation (useful for digging into revenue mix, surgical volume trends and detailed expense commentary). Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: News outlets published Q1 snapshots and highlights summarizing top‑line growth and items to watch in management commentary. Earnings Highlights Earnings Snapshot
• Negative Sentiment: Q1 results: revenue topped estimates ($61.46M vs. ~$57.9M expected) but EPS of $0.07 missed consensus (~$0.11–$0.12). Management cited rising expenses; the company still shows a negative net margin and negative ROE—factors that weighed on investor sentiment. Earnings Miss / Expenses
• Negative Sentiment: Zacks Research downgraded AxoGen from “hold” to “strong sell,” increasing downside sentiment and potentially pressuring short‑term flows. Zacks Downgrade

Wall Street Analyst Weigh In

AXGN has been the topic of several recent research reports. Citizens Jmp upped their price objective on AxoGen from $42.00 to $50.00 and gave the company a “market outperform” rating in a research report on Wednesday. Wall Street Zen downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. HC Wainwright upped their price objective on AxoGen from $39.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday. Canaccord Genuity Group upped their price objective on AxoGen from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Lake Street Capital upped their price objective on AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.50.

AxoGen Price Performance

The company has a 50-day moving average of $33.49 and a two-hundred day moving average of $30.29. The stock has a market capitalization of $2.17 billion, a PE ratio of -122.85 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 5.11 and a quick ratio of 3.31.

AxoGen (NASDAQ:AXGN) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.04). AxoGen had a negative return on equity of 13.44% and a negative net margin of 6.97%.The business had revenue of $61.46 million for the quarter, compared to analysts’ expectations of $57.85 million. Sell-side analysts predict that AxoGen, Inc. will post -0.24 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Erick Wayne Devinney sold 5,221 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $32.84, for a total transaction of $171,457.64. Following the transaction, the insider directly owned 262,781 shares in the company, valued at approximately $8,629,728.04. This represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 2.78% of the company’s stock.

Hedge Funds Weigh In On AxoGen

Large investors have recently modified their holdings of the company. MCF Advisors LLC purchased a new position in shares of AxoGen in the 4th quarter worth about $30,000. Arax Advisory Partners raised its holdings in shares of AxoGen by 362.4% in the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 819 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of AxoGen in the 4th quarter worth about $36,000. Kestra Advisory Services LLC purchased a new position in shares of AxoGen in the 4th quarter worth about $39,000. Finally, Aquatic Capital Management LLC raised its holdings in shares of AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 1,269 shares during the period. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.